Nanthealth LLC (NYSE:NH) shares were down 3% on Friday . The stock traded as low as $13.30 and last traded at $13.57, with a volume of 55,941 shares. The stock had previously closed at $13.99.

Several research analysts have weighed in on NH shares. Jefferies Group started coverage on Nanthealth in a report on Monday, June 27th. They set a “buy” rating on the stock. Canaccord Genuity initiated coverage on Nanthealth in a report on Monday, June 27th. They issued a “buy” rating and a $17.00 price target on the stock. Cowen and Company initiated coverage on Nanthealth in a report on Monday, June 27th. They issued an “outperform” rating and a $19.00 price target on the stock. FBR & Co initiated coverage on Nanthealth in a report on Monday, June 27th. They issued an “outperform” rating and a $18.00 price target on the stock. Finally, First Analysis initiated coverage on Nanthealth in a report on Monday, June 27th. They issued an “overweight” rating and a $18.00 price target on the stock. Five research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $18.00.

The company’s 50 day moving average price is $13.88 and its 200 day moving average price is $13.88. The stock’s market cap is $7.61 billion.

In related news, CEO Patrick Soon-Shiong acquired 357,143 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $5,000,002.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Healthcare Solution Allscripts acquired 714,286 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The stock was bought at an average price of $14.00 per share, with a total value of $10,000,004.00. Following the completion of the acquisition, the insider now directly owns 15,000,000 shares of the company’s stock, valued at $210,000,000. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.